TREATMENT
Combination Therapy Shows Activity in KRAS G12C-Mutated Metastatic CRCA phase 1b/2 trial found that ifebemtinib plus garsorasib demonstrated anticancer activity and manageable safety in previously treated patients with KRAS G12C-mutated metastatic colorectal cancer, though the improvement in response rate did not reach statistical significance. (The Lancet Oncology)